🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05364736
Starting soon Not applicable

Effect of Prebiotics on Blood Pressure Management

NCT05364736 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Not applicable
Started
2022-10-17
Last updated
2022-05-06

Condition(s) studied

HypertensionGastrointestinal Microbiome

Investigational drug(s) / intervention(s)

Highland barley β-glucan dietary supplementPlacebo controls

Highland barley β-glucan dietary supplement: 100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks

Placebo controls: Placebo with a similar appearance and taste to highland barley β-glucan supplement

Study summary

This survey is designed to investigate the effect of highland barley β-glucan supplementation on the regulatory of blood pressure, gut microbiota and cardiovascular risk fators in subjects with hypertention.

Eligibility

Sex
ALL
Min age
30 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age:30-65 years old 2. Newly diagnosed hypertension did not use antihypertensive drugs OR Systolic blood pressure ≥140mmHg on the physical examination OR Diastolic blood pressure ≥90mmHg on the physical examination. 3. BMI≥18 kg/m2 Exclusion Criteria: 1. Receiving or have been treated with antihypertensive drugs. 2. Complications including cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke. 3. Severe liver or renal insufficiency (alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase is greater than 3 times the upper limit of normal OR GFR\<30ml/min/1.73m2). 4. Autoimmune diseases or thyroid diseases. 5. Women who are pregnant, nursing, or prepare to give birth during the trail. 6. Malignant disease, infectious disease, inflammatory disease and advanced liver disease. 7. Mental or intellectual abnormalities, unable to sign informed consent. 8. Complications including chronic gastrointestinal disease; or suffered from acute gastrointestinal diseases within 1 months before screening visit. 9. Received antibiotics, probiotics within 3 months before screening visit or throughout the trail. 10. Major operations were performed within six months of screening visit, or will be made during the trial. 11. Alcohol abuse (alcohol intake\>60g/d for male and alcohol intake\>40g/d for female)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-Sen University Guangzhou Guangdong

More Sun Yat-sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05364736 on ClinicalTrials.gov ↗ ← All trials in China